SLC5A2 and Myocardial fibrosis: Inhibit sodium-glucose co-transporter 2 (SGLT2), improve insulin sensitivity, reduce myocardial fibrosis; reduce oxidative stress and enhance mitochondrial function, improving cardiac function in diabetic cardiomyopathy.